How many times can you take Erdafitinib a year?

Erdafitinib (Erdafitinib) is the first targeted therapy drug to receive accelerated approval from the FDA for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC). To be eligible, UC must have sensitizing fibroblast growth factor receptor (FGFR) 3 or FGFR2 gene alterations and have progressed during or after at least one prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Based on current clinical guidelines, oral administration of erdafitinib once daily is generally recommended. However, the specific frequency and dosage of medication should be determined based on the patient's specific situation, including the severity of the condition, the patient's overall health, and other medications. The recommended dose is 8 mg orally once daily, with the dose increased to 9 mg once daily on days 14 to 21 based on serum phosphate (PO4) levels and tolerance (three 3 mg tablets). Patients need to clarify their own medication plan based on the doctor's advice and individual circumstances to ensure the correct use of the drug.

The original version of erdafitinib has not yet been launched in China, so it cannot be covered by medical insurance. The original version of erdafitinib currently sold in Hong Kong may cost more than 20,000 yuan per box of specifications 4mg*14 tablets (the price may fluctuate due to exchange rates). Cheaper erdafitinib generic drugs produced by other pharmaceutical factories are also sold overseas. The pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 4mg*60 tablets produced by a Bangladeshi pharmaceutical factory may be more than 3,000 yuan per box (the price may fluctuate due to exchange rates).